The urothelial carcinoma treatment market is evolving from a historically chemotherapy-centered space into a more biomarker-guided, multimodal, and sequencing-driven oncology market. Urothelial carcinoma, which arises predominantly in the bladder and also in the renal pelvis, ureter, and urethra, is treated across non-muscle-invasive, muscle-invasive, locally advanced, and metastatic settings, creating demand across hospital oncology departments, specialty cancer centers, ambulatory infusion networks, and academic institutes. The most important end uses remain first-line management of advanced disease, perioperative treatment around cystectomy in high-risk muscle-invasive disease, recurrence management in non-muscle-invasive disease, and later-line treatment for relapsed or refractory patients. The market’s center of gravity has shifted toward immune checkpoint inhibitors, antibody-drug conjugates, and targeted therapy for genomically selected patients, while chemotherapy continues to retain a meaningful role in fit patients and combination regimens. Recent treatment advances, including wider use of enfortumab vedotin plus pembrolizumab in advanced disease, sustained adjuvant use of nivolumab, and the continued positioning of erdafitinib for FGFR3-altered disease, show how the category is moving toward precision-based treatment pathways. At the same time, competitive intensity has increased as older accelerated pathways have been reevaluated, including the withdrawal of sacituzumab govitecan’s urothelial carcinoma indication, reinforcing a more evidence-driven commercial environment.